0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Journal Articles

in Pharmacogenetics

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Original Investigation  | 
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms A Meta-analysis
Maria Schwaederle, PharmD; Melissa Zhao, BS; J. Jack Lee, PhD; et al.
JAMA Oncology
Original Investigation  | 
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer A Secondary Analysis of the PETACC-8 Randomized Clinical Trial
Valérie Boige, MD, PhD; Marc Vincent, PhD; Philippe Alexandre, MS; et al.
JAMA Oncology
Editorial  | 
Oral Cancer Chemoprevention—The End of EPOC, the Beginning of an Epoch of Molecular Selection
Julie E. Bauman, MD, MPH; Jennifer Grandis, MD
JAMA Oncology
Original Investigation  | 
Erlotinib and the Risk of Oral Cancer The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial
William N. William Jr, MD; Vassiliki Papadimitrakopoulou, MD; J. Jack Lee, PhD; et al.